{
  "url": "https://www.nasdaq.com/article/bioinformatics-instrument-maker-10x-genomics-sets-terms-for-297-million-ipo-cm1206596",
  "title": "Bioinformatics instrument-maker 10x Genomics sets terms for $297 million IPO - Nasdaq.com",
  "text": [
    " 10x Genomics, which makes instruments and other technology for analyzing biological information, announced terms for its IPO on Tuesday.    The Pleasanton, CA-based company plans to raise $297 million by offering 9 million shares at a price range of $31 to $35. At the midpoint of the proposed range, 10x Genomics would command a fully diluted market value of $3.5 billion.    10x Genomics was founded in 2012 and booked $197 million in sales for the 12 months ended June 30, 2019. It plans to list on the Nasdaq under the symbol TXG. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch are the joint bookrunners on the deal. It is expected to price during the week of September 9, 2019.  The article Bioinformatics instrument-maker 10x Genomics sets terms for $297 million IPO  originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.   Investment Disclosure:  The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO)  , Renaissance International ETF (symbol: IPOS)  , or separately managed institutional accounts may have investments in securities of companies mentioned.",
    "10x Genomics, which makes instruments and other technology for analyzing biological information, announced terms for its IPO on Tuesday.    The Pleasanton, CA-based company plans to raise $297 million by offering 9 million shares at a price range of $31 to $35. At the midpoint of the proposed range, 10x Genomics would command a fully diluted market value of $3.5 billion.    10x Genomics was founded in 2012 and booked $197 million in sales for the 12 months ended June 30, 2019. It plans to list on the Nasdaq under the symbol TXG. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch are the joint bookrunners on the deal. It is expected to price during the week of September 9, 2019.",
    "\nThe views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.\n"
  ],
  "published_datetime": "2019-09-03 08:59:00"
}